FCRN antagonist molecules and methods of use thereof

By developing a novel FcRn antagonist molecule, specifically binds and inhibits the binding of IgG to FcRn, the problem of prolonging IgG half-life is solved, and the level of serum IgG antibodies is achieved rapidly, and the effect of treating autoimmune diseases and inflammatory diseases is achieved.

CN120344557APending Publication Date: 2025-07-18ARGENX BVBA(BE)
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
CN202380082826.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-11-14
Filing Date
2023-11-14
Publication Date
2025-07-18

AI Technical Summary

Technical Problem

In the prior art, the binding of FcRn to IgG leads to an extended half-life of IgG, which cannot effectively reduce the therapeutic effect of autoimmune diseases and inflammatory diseases. Antagonists are needed to prevent the binding of IgG to FcRn to regulate serum IgG levels.

Method used

A novel FcRn antagonist molecule was developed to reduce the serum IgG antibody level of subjects by specifically binding to FcRn and inhibiting the binding of IgG to FcRn, and to form a stable composition using the dimer domain of the variant Fc region, including specific amino acid sequences and glycan modifications.

Benefits of technology

Rapidly reduce subjects' serum IgG antibody levels, showing long-term stability, and are effective in the treatment of autoimmune and inflammatory diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005428489240000141
    Figure BDA0005428489240000141
  • Figure BDA0005428489240000142
    Figure BDA0005428489240000142
  • Figure BDA0005428489240000151
    Figure BDA0005428489240000151
Patent Text Reader

Abstract

The present disclosure provides populations of FcRn antagonist molecules, mixtures of these populations, and methods of using these populations to reduce serum IgG autoantibody levels in a subject.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Methods and transformed mammalian lymphocytic cells for producing functional antigen-binding protein including chimeric immunoglobulin and fragments

    US5807715A

  • Method of eliminating inhibitory / instability regions of mRNA

    US5965726A

  • Method of eliminating inhibitory / instability regions from mRNA

    US6174666B1

  • Method of eliminating inhibitory / instability regions of mRNA

    US6291664B1

  • Method of eliminating inhibitory / instability regions of mRNA

    US6414132B1